We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Study Explains Link between Genetic Variation and Vaccine Specificity and Persistence

By LabMedica International staff writers
Posted on 24 Jun 2019
To better explain how genetic variation affects antibody production and specificity following immunization, researchers conducted a GWAS (genome-wide association study) to examine the persistence of immunity following administration of three childhood vaccines.

The efficacy of vaccine-induced immunity depends on the considerable variability in magnitude and persistence of specific antibodies. More...
Maintenance of these specific antibodies is essential for continuity of vaccine-induced serological protection.

Investigators at the University of Oxford (United Kingdom) conducted a genome-wide association study into the persistence of immunity to three childhood vaccines: capsular group C meningococcal (MenC), Haemophilus influenzae type b, and tetanus toxoid (TT) vaccines. Working with genetic data collected from 3,602 children in the United Kingdom and The Netherlands, the investigators analyzed approximately 6.7 million genetic variants affecting single nucleotide polymorphisms (SNPs) associated with vaccine-induced antibody levels.

Following analysis of the results, the investigators published detailed associations between variants in a locus containing a family of signal-regulatory proteins and the persistence of MenC immunity.

"Evoking robust and sustained vaccine-induced immunity from early life is a crucial component of global health initiatives to combat the burden of infectious disease," said first author Dr. Daniel O'Connor, postdoctoral researcher in pediatrics at the University of Oxford. "The mechanisms underlying the persistence of antibody are of major interest, since effectiveness and acceptability of vaccines would be improved if protection were sustained after infant immunization without the need for repeated boosting through childhood."

The vaccine study was published in the June 11, 2019, online edition of the journal Cell Reports.

Related Links:
University of Oxford


New
Gold Member
Genetic Type 1 Diabetes Risk Test
T1D GRS Array
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Industry

view channel
Image: The LIAISON NES molecular point-of-care platform (Photo courtesy of Diasorin)

Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform

Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.